Systemic antifungal therapy for proven or suspected invasive candidiasis: the AmarCAND 2 study

Annals of Intensive Care

Volumn 6, Issue 1, 2016, Pages 1-11

  Leroy, Olivier ^a   Bailly, Sébastien ^b   Gangneux, Jean Pierre ^c   Mira, Jean Paul ^d   Devos, Patrick ^e   Dupont, Hervé ^f   Montravers, Philippe ^g   Perrigault, Pierre François ^h   Constantin, Jean Michel ⁱ   Guillemot, Didier ^j   Azoulay, Elie ^k   Lortholary, Olivier ^l   Bensoussan, Caroline ^m   Timsit, Jean François ^g  

^a Intensive Care Unit   (France)

^b UNIV GRENOBLE ALPES   (France)

^c RENNES UNIVERSITY HOSPITAL   (France)

^d Institut Cochin   (France)

^e LILLE UNIVERSITY HOSPITAL   (France)

^f AMIENS UNIVERSITY HOSPITAL   (France)

^g BICHAT HOSPITAL   (France)

^h MONTPELLIER UNIVERSITY HOSPITAL   (France)

ⁱ UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^j INSTITUT PASTEUR   (France)

^k SAINT LOUIS HOSPITAL   (France)

^l HÔPITAL NECKER ENFANTS MALADES   (France)

^m MSD France   (France)

more..

Author keywords

Candida; Candidaemia; Candidiasis; Cohort study; Critically ill; Intensive care

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ANTIFUNGAL AGENT; CASPOFUNGIN; ECHINOCANDIN; FLUCONAZOLE; FLUCYTOSINE; MICAFUNGIN; VORICONAZOLE;

ADULT; ARTICLE; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDEMIA; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; FRANCE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTENSIVE CARE UNIT; INVASIVE CANDIDIASIS; MAJOR CLINICAL STUDY; MALE; MORTALITY RATE; MULTICENTER STUDY; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSTIC ASSESSMENT; SEPTIC SHOCK;

EID: 84953707428     PISSN: None     EISSN: 21105820     Source Type: Journal    
DOI: 10.1186/s13613-015-0103-7     Document Type: Article

References (31)

1. Vincent JL, Rello J, Marshall J, et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA. 2009;302:2323–9.
2. Kett DH, Azoulay E, Echeverria PM, et al. Candida bloodstream infections in intensive care units: analysis of the extended prevalence of infection in intensive care unit study. Crit Care Med. 2011;39:665–70.
3. Cornely OA, Bassetti M, Calandra T, et al. ESCMID guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect. 2012;18(Suppl 7):19–37.
4. Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009;48:503–35.
5. Tabah A, Koulenti D, Laupland K, et al. Characteristics and determinants of outcome of hospital-acquired bloodstream infections in intensive care units: the EUROBACT International Cohort Study. Intensive Care Med. 2012;38:1930–45.
6. Blot S, Charles PE. Fungal sepsis in the ICU: are we doing better? Trends in incidence, diagnosis, and outcome. Minerva Anestesiol. 2013;79:1396–405.
7. Leon C, Ostrosky-Zeichner L, Schuster M. What’s new in the clinical and diagnostic management of invasive candidiasis in critically ill patients. Intensive Care Med. 2014;40:808–19.
8. Cuenca-Estrella M, Verweij PE, Arendrup MC, et al. ESCMID guideline for the diagnosis and management of Candida diseases 2012: diagnostic procedures. Clin Infect Dis. 2012;18(Suppl 7):9–18.
9. Nguyen MH, Wissel MC, Shields RK, et al. Performance of Candida real-time polymerase chain reaction, beta-D-glucan assay, and blood cultures in the diagnosis of invasive candidiasis. Clin Infect Dis. 2012;54:1240–8.
10. Kollef M, Micek S, Hampton N, et al. Septic shock attributed to Candida infection: importance of empiric therapy and source control. Clin Infect Dis. 2012;54:1739–46.
11. Garey KW, Rege M, Pai MP, et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis. 2006;43:25–31.
12. Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother. 2005;49:3640–5.
13. Colombo AL, Guimaraes T, Sukienik T, et al. Prognostic factors and historical trends in the epidemiology of candidemia in critically ill patients: an analysis of five multicenter studies sequentially conducted over a 9-year period. Intensive Care Med. 2014;40:1489–98.
14. Arendrup MC, Sulim S, Holm A, et al. Diagnostic issues, clinical characteristics, and outcomes for patients with fungemia. J Clin Microbiol. 2011;49:3300–8.
15. Puig-Asensio M, Padilla B, Garnacho-Montero J, et al. Epidemiology and predictive factors for early and late mortality in Candida bloodstream infections: a population-based surveillance in Spain. Clin Microbiol Infect. 2014;20:O245–54.
16. Leon C, Ruiz-Santana S, Saavedra P, et al. Usefulness of the “Candida score” for discriminating between Candida colonization and invasive candidiasis in non-neutropenic critically ill patients: a prospective multicenter study. Crit Care Med. 2009;37:1624–33.
17. Ostrosky-Zeichner L, Pappas PG, Shoham S, et al. Improvement of a clinical prediction rule for clinical trials on prophylaxis for invasive candidiasis in the intensive care unit. Mycoses. 2009;54:46–51.
18. Eggimann P, Pittet D. Candida colonization index and subsequent infection in critically ill surgical patients: 20 years later. Intensive Care Med. 2014;40:1429–48.
19. Leroy O, Gangneux JP, Montravers P, et al. Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France (2005–2006). Crit Care Med. 2009;37:1612–8.
20. Azoulay E, Dupont H, Tabah A, et al. Systemic antifungal therapy in critically ill patients without invasive fungal infection. Crit Care Med. 2012;40:813–22.
21. Parmeland L, Gazon M, Guerin C, et al. Candida albicans and non-Candida albicans fungemia in an institutional hospital during a decade. Med Mycol. 2013;51:33–7.
22. Arendrup MC, Dzajic E, Jensen RH, et al. Epidemiological changes with potential implication for antifungal prescription recommendations for fungaemia: data from a nationwide fungaemia surveillance programme. Clin Microbiol Infect. 2013;19:E343–53.
23. Das I, Nightingale P, Patel M, et al. Epidemiology, clinical characteristics, and outcome of candidemia: experience in a tertiary referral center in the UK. Int J Infect Dis. 2011;15:e759–63.
24. Ericsson J, Chryssanthou E, Klingspor L, et al. Candidaemia in Sweden: a nationwide prospective observational survey. Clin Microbiol Infect. 2013;19:E218–21.
25. Pfaller MA, Andes DR, Diekema DJ, et al. Epidemiology and outcomes of invasive candidiasis due to non-albicans species of Candida in 2,496 patients: data from the Prospective Antifungal Therapy (PATH) registry 2004–2008. PLoS One. 2014;9:e101510.
26. Lortholary O, Renaudat C, Sitbon K, et al. Worrisome trends in incidence and mortality of candidemia in intensive care units (Paris area, 2002–2010). Intensive Care Med. 2014;40:1303–12.
27. Paugam A, Ancelle T, Lortholary O, et al. Longer incubation times for yeast fungemia: importance for presumptive treatment. Diag Microbiol Infect Dis. 2014;80:119–21.
28. Guery BP, Arendrup MC, Auzinger G, et al. Management of invasive candidiasis and candidemia in adult non-neutropenic intensive care unit patients: part I Epidemiology and diagnosis. Intensive Care Med. 2009;35:55–62.
29. Bruyere R, Quenot JP, Prin S, Dalle F, Vigneron C, Aho S, et al. Empirical antifungal therapy with an echinocandin in critically-ill patients: prospective evaluation of a pragmatic Candida score-based strategy in one medical ICU. BMC Infect Dis. 2014;14:385.
30. Wisplinghoff H, Seifert H, Tallent SM, et al. Nosocomial bloodstream infections in pediatric patients in United States hospitals: epidemiology, clinical features and susceptibilities. Ped Infect Dis J. 2003;22:686–91.
31. Charles PE, Doise JM, Quenot JP, Aube H, Dalle F, Chavanet P, et al. Candidemia in critically ill patients: difference of outcome between medical and surgical patients. Intensive Care Med. 2003;29(12):2162–9.